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28 Oral Presentations0 (0–2), respectively. The median number of hospital admissions
per patient was 1 (range 0–4). The reasons for acute care/ER visits
and hospital admissions were tabulated below.
Reasons for acute care/ER visits and hospital
admissionsAcute care/ER visits fever (n523), bacteremia (2), dehydration (6),
bronchiolitis (1), hemolysis (1), gastrointestinal
bleeding (1), pseudotumor cerebri (2), bandemia
(1)
Hospital admissions conditioning (n58), fever with no positive
cultures (14), bacteremia (8), dehydration (4),
bronchiolitis (1), hemolysis (1), gastrointestinal
bleeding (1), pseudotumor cerebri (1), bandemia
(1), CMV (1)In 82.5% of hospital admissions (33/40), the clinical course was
non-complex, with the discharge diagnosis the same as the admission
diagnosis. In 17.5% (7/40), the course was complicated by conditions
that developed while patients were in hospital, including bacteremia
(n5 3), sepsis (3), adenovirus (1), respiratory distress (2), gastrointes-
tinal bleeding (3), and organ failure (2). The median length of the
non-complex and complex hospitalizations was 4 days (range 1–38)
and 50 days (9–80), respectively. On any day, the mean probability
that a patient would be an out-patient was 78.6% (CI 77.0–
80.1%); the probability that the patient would be an in-patient for
a non-complex or complex stay was 8.8% and 12.6%, respectively
(CI 7.3–10.8% and 11.6–13.6%). In an earlier cohort, in which the
busulfan AUC target was 4000–4600 microM-min (n 5 17), 4 pa-
tients had primary graft failure and 3 died from related complica-
tions. In a later cohort with an AUC target of 5000 (n 5 9), no
patients had primary graft failure or death. Survival in these 2 cohorts
was 81.2 and 100%, respectively (median follow-up 32.2 and 10.5
months). All engrafted patients have stable donor chimerism, im-
proved lymphocyte counts, normalized immune function and de-
creased susceptibility to infection. Our data showed that
ambulatory HSCT utilizing a RIC regimen was highly effective in
children with PID.67
IMPACT OF REDUCED INTENSITY CONDITIONING (RIC) IN PEDIATRIC
ACUTE LYMPHOBLASTIC LEUKEMIA (ALL): A REPORT FROM THE CIBMTR
Verneris, M.R., Burke, M.J., He, W., Davies, S.M., Eapen, M.,
Wagner, J.E. CIBMTR, Milwaukee, WI
Significant experience now exists with reduced intensity condi-
tion (RIC) regimens prior to allogeneic hematopoietic cell trans-
plantation (HCT) in adults with acute myeloid leukemia and
non-ALL, lymphoid malignancies. Due to concerns that ALL
may require more intensive therapy, there are few reports on the
use of RIC, particularly in children with ALL. Therefore, we eval-
uated the transplant outcomes after RIC and allogeneic HCT in 41
children with ALL. In this retrospective analysis, all patients were
aged 0–18 years with 64% aged 11–18 years; 44% had a Karnofsky
score of\90%; and the disease status at the time of transplant was:
1st complete remission (CR) in 13%, 2nd CR in 41%, and .2nd CR
in 26% and 21% had active disease. The time from diagnosis to
transplant for 1st CR patients was 9 months (8–62 months) and
for $2nd CR patients it was 32 months after 1st CR (range, 6–89
months). 63% were transplanted after 2000. A TBI-based condi-
tioning regimen was used in 33% of patients, while the remainder
(66%) received non-TBI containing regimens consisting of: busul-
fan (34%), cyclophosphamide (15%) and melphalan (17%).
Matched related donors, were available for 37% (50% BM and
50% PBSC), with the remaining (63%) having unrelated donors
(BM in 19%, PBSC in 55% and cord blood in 23%). Most had
GVHD prophylaxis with a calcineurin inhibitor in combination
with either methotrexate (47%) or other agents (41%). The disease
free survival (DFS) and overall survival (OS) at 3 yrs was 31% (95%CI, 16–47%) and 38% (95%CI, 22–54%), respectively. Transplant
related mortality (TRM) at 100 days and 3 years was 18% (95%
confidence interval (CI, 7–30%) and 30% (95% CI, 16–46%).
The incidence of aGVHD (Grade II-IV) at day 1100 was 35%.
At 3 years, cGHVD developed in 23% of patients. Relapse at 3
years was 39% (95% CI, 23–57). This is the largest series describ-
ing outcomes in pediatric patients with ALL undergoing allogeneic
HCT after a RIC. While additional analyses are required, these
data demonstrate that long termDFS andOS can be achieved using
RIC regimens in pediatric patients with ALL.SOLID TUMORS
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ADOPTIVE TRANSFER OF HER2-SPECIFIC T CELLS ERADICATES EXPERI-
MENTAL GLIOBLASTOMA MULTIFORME
Salsman, V.S.1, Kew, Y.2, Powell, S.Z.2, Wels, W.E.3, Grossman, R.2,
Heslop, H.E.1,2, Gottschalk, S.1, Ahmed, N.1 1Baylor College of Medicine,
Houston, TX; 2Weil-Cornell Medical College, Houston, TX; 3Georg-
Speyer-Haus, Frankfurt Am Main, Germany
Background: The intent of this project is to develop an effective
adoptive immunotherapy for glioblastoma multiforme (GBM),
which remains largely incurable with current treatment disciplines.
New therapies are thus needed to improve current outcomes with-
out increasing treatment-related morbidities. Immunotherapies
have the potential to fulfill this need, since they are highly tumor-
specific and cause minimal bystander cell damage. We propose to
use T cells to target the human epidermal growth factor receptor
2 (HER2), a surface antigen, which is overexpressed in GBM.
While the use of HER2 monoclonal antibodies has been limited
by low levels of HER2 expression on GBMs, we show here that
T cells expressing HER2-specific chimeric antigen receptors
(CAR) have potent anti-tumor activity both ex vivo and in animal
models.
Methods:T cells fromGBM patients were retroviraly transduced
to express HER2-specific CAR with a CD28.z signaling domain
(HER2-specific T cells). Primary GBM cells and GBM cell lines
were used to test the function of the generated HER2-specific T
cells. The ex vivo efficacy was determined by their ability 1) to kill
HER2-positive target cells in a cytoxicity assay and 2) to proliferate
and secrete cytokines (IFN-g and IL-2) in response to stimulation
with HER2-positive tumor cells. The in vivo efficacy of the
HER2-specific T cells was tested for the ability to induce tumor re-
gression in an orthotopic murine xenograft model.
Results: Primary HER2-specific T cells killed both HER2-pos-
itive autologous GBM cells and GBM cell lines in cytotoxicity
assays, whereas HER2-negative targets were not killed. Stimulation
of HER2-specific T cells with HER2-positive primary GBM cells
and GBM cell lines resulted in T-cell proliferation and secretion
of IFN-g and IL-2 in aHER2-dependentmanner. Intra-tumoral in-
jection of HER2-specific T cells resulted in eradication of estab-
lished GBM xenografts in an orthotopic murine model. In
contrast, delivery of non-transduced T cells did not change the
tumor growth pattern.
Conclusion: We demonstrate that T-cells expressing HER2-
specific CARs can recognize and kill HER2-positive GBMs. Their
activation results in proliferation and secretion of immunostiumla-
tory cytokines. HER2-specific T cells can effectively eradicate
established GBM xenografts in an orthotopic murine model. These
results indicate that HER2-specific T cells could represent a promis-
ing immunotherapeutic approach for GBM.STEM CELL BIOLOGY
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IDENTIFICATION AND ISOLATION OF THE HEMATOPOIETIC STEM CELL
NICHE INITIATING CELL POPULATION
Kraft, D., Chan, C., Chen, C.-C., Luppen, C., Weissman, I.L. Stanford
University School of Medicine, Stanford, CA
Introduction: Identification and understanding of the cells and
processes that can generate, sustain and influence the HSC niche and
